Proteoglycans are complex polydisperse macromolecules with a central protein core which binds a large number of negatively charged carbohydrate side chains. Cartilage proteoglycans vary with the anatomical origin and depth of cartilage and the age of the subject from whom they were extracted.'9 20 The core protein of larger cartilage proteoglycans (molecular weight 210 000) shares many antigenic sites and peptide similarities, however, though greater variation has been shown for smaller proteoglycans.9 Monomers of cartilage proteoglycans from different sources were used as an antigen in this study and were purified and stored under similar conditions to those used by other workers. Some studies appear to have used pooled sources of cartilage proteoglycans as antigens.5 Concentrations of cartilage proteoglycans used in studies reporting a response to cartilage proteoglycans were higher than in our study4-typically 30-50 tg/ml compared with our range of 0-1-20 Fg/ml, though in view of the heterogeneity of cartilage proteoglycans direct comparisons may not be valid. This heterogeneity of cartilage proteoglycans may provide an explanation for the variety of responses described in inflammatory arthritis. These factors and the ubiquitous release of cartilage proteoglycans in joint diseases makes it difficult to envisage a role for cartilage proteoglycans as autoantigens. In addition studies implicating cartilage proteoglycans in the pathogenesis of ankylosing spondylitis do not account for the genetic basis of this disease. There appear to be no other methodological differences in the cell proliferation assays performed here compared with those of other studies. Earlier studies have measured the production of leucocyte inhibitory factor as indicative of antigen responses. It has been suggested that these methods may measure different aspects of cellular immunity and may be more sensitive.6
In summary we have tested a large number of patients with ankylosing spondylitis for evidence of cellular immunity to purified monomers of cartilage proteoglycans using a range of preparations and have compared the responses with healthy control subjects matched for age. There was no evidence of a specific response in patients with ankylosing spondylitis. Variations in preparations of cartilage proteoglycans may account for the differing responses described in previous studies due to the heterogeneity of human cartilage proteoglycans.
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